The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Malfertheiner P.

Megraud F.

O'Morain C.A.

Atherton J.

Axon A.Т.R

Bazzoli F.

Gensini G.F.

Gisbert J.P.

Graham D.Y.

Rokkas T.

El-Omar E.M.

Kuipers E.J.

Management of Helicobacter pylori infection - the Maastricht-IV/Florence Consensus Report

Authors:

Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.Т.R, Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2012;(2): 35‑62

Read: 8874 times

Download PDF (RU)
Contact the author
Table of contents

MANAGEMENT OF HELICOBACTER PYLORI INFECTION - THE MAASTRICHT-IV/FLORENCE CONSENSUS REPORT.
MANAGEMENT OF HELICOBACTER PYLORI INFECTION - THE MAASTRICHT-IV/FLORENCE CONSENSUS REPORT.

To cite this article:

Malfertheiner P, Malfertheiner P, Megraud F, et al. . Management of Helicobacter pylori infection - the Maastricht-IV/Florence Consensus Report. Russian Journal of Evidence-Based Gastroenterology. 2012;(2):35‑62. (In Russ.)

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Gut 2012; 61: 646-664

Authors:

Malfertheiner P.

Megraud F.

O'Morain C.A.

Atherton J.

Axon A.Т.R

Bazzoli F.

Gensini G.F.

Gisbert J.P.

Graham D.Y.

Rokkas T.

El-Omar E.M.

Kuipers E.J.

Close metadata

References:

  1. Malfertheiner P., Megraud F., O'Morain C. et al. Current European concepts in the management of helicobacter pylori infection - the Maastricht consensus report. The European helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1-2.
  2. Malfertheiner P., Megraud F., O'Morain C. et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180.
  3. Malfertheiner P., Megraud F., O'Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781.
  4. Howden C.W., Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on practice Parameters of the American College of gastroenterology. Am J Gastroenterol 1998; 93: 2330-2338.
  5. Vaira D., Malfertheiner P., Megraud F. et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 1999; 354: 30-33.
  6. Chiba N., Van Zanten S.J., Sinclair P. et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 1012-1016.
  7. Moayyedi P., Axon A.T. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 3122-3125.
  8. Ikenberry S.O., Harrison M.E., Lichtenstein D. et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2007; 66: 1071-1075.
  9. Niv Y., Niv G., Koren R. 13C-urea breath test for diagnosis of Helicobacter pylori infection in the elderly. Dig Dis Sci 2004; 49: 1840-1844.
  10. Moayyedi P., Deeks J., Talley N.J. et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-2626.
  11. Harvey R.F., Lane J.A., Nair P. et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010; 32: 394-400.
  12. Maconi G., Sainaghi M., Molteni M. et al. Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication - a 7-year follow-up study. Eur J Gastroenterol Hepatol 2009; 21: 387-393.
  13. Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007; 21: 347-361.
  14. Gwee K.A., Teng L., Wong R.K. et al. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009; 21: 417-424.
  15. Jin X., Li Y.M. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12: 541-546.
  16. El-Omar E.M., Oien K., EI-Nujumi A. et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
  17. De Vries A.C., van Grieken N.C., Looman C.V.V. et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134: 945-952.
  18. Cullen D., Hawkey G., Greenwood D. et al. H. pylori and gastroesophageal reflux disease: a community-based study. Helicobacter 2008; 13: 352-360.
  19. O'Connor H.J. Review article: helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther 1999; 13: 117-127.
  20. Rokkas T., Pistiolas D., Sechopoulos P. et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-17, 1417.
  21. Yaghoobi M., Farrokhyar F., Yuan Y. et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007-1013.
  22. Moayyedi P., Bardhan C., Young L. et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-1126.
  23. Qian B., Shijie M., Shang L. et al. Effect of H. pylori eradication on gastroesophageal reflux disease. Helicobacter 2011; 16: 255-265.
  24. Klinkenberg-Knol E.C., Nelis F., Dent J. et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safetyand influence on gastric mucosa. Gastroenterology 2000; 118: 661-669.
  25. Di Mario F., Ingegnoli A., Dal Bò N. et al. Early epigastric pain after PPI administration: exacerbation of Helicobacter pylori corpus gastritis? Helicobacter 2004; 9: 92-94.
  26. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
  27. Chan F.K., Sung J.J., Chung S.C. et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
  28. Chan F.K., To K.F., Wu J.C. et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
  29. de Leest H.T., Steen K.S., Lems W.F. et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12: 477-485.
  30. Lai K.G., Lau C.S., Ip W.Y. et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: 799-805.
  31. Hawkey C.J., Tulassay I., Szczepanski L. et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021.
  32. Vergara M., Catalan M., Gisbert J.P. et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-1418.
  33. Chan F.K., Chung S.C., Suen B.Y. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973.
  34. Lai K.C., Lam S.K., Chu K.M. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. A/ Engl J Med 2002; 346: 2033-2038.
  35. Chan F., Ching J., Suen B. et al. H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-tisk aspirin users: a 10-year prospective cohort study (abstr). Gastroenterology 2011; 140: 5173-5174.
  36. Schenk B.E., Kuipers E.J., Nelis G.F. et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-621.
  37. Lundell L., Havu N., Miettinen P. et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 639-647.
  38. Moayyedi P., Wason C., Peacock R. et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-214.
  39. Kuipers E.J., Lundell L., Klinkenberg-Knol E.C. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-1022.
  40. Hagiwara T., Mukaisho K., Nakayama T. et al. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011; 60: 624-630.
  41. Fox J.G., Kuipers E.J. Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut 2011; 60: 567-568.
  42. Malfertheiner P., Sipponen P., Naumann M. et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005; 100: 2100-2115.
  43. Correa P., Fontham E.T., Bravo J.C. et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-1888.
  44. Leung W.K., Lin S.R., Ching J.Y. et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-1249.
  45. Wong B.C., Lam S.K., Wong W.M. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194.
  46. Wang J., Xu L., Shi R. et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011: 83: 253-260.
  47. Wotherspoon A.C., Doglioni C., Diss T.C. et al. Regression of primary low-grade B-ceil gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577.
  48. Chen L.T., Lin J.T., Tai J.J. et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-1353.
  49. Stathis A., Chini C., Bertoni F. et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009; 20: 1086-1093.
  50. Wundisch T., Thiede C., Morgner A. et al. Long-term follow-up of gastric MALTlymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024.
  51. Ruskone-Fourmestraux A., Fischbach W., Aleman B.M. et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758.
  52. Qu X.H., Huang X.L., Xiong P. et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010; 16: 886-896.
  53. Muhsen K., Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323-340.
  54. Pellicano R., Franceschi F., Saracco G. et al. Helicobacters and extragastric diseases. Helicobacter 2009; 14 (Suppl 1): 58-68.
  55. Arnold D.M., Bernotas A., Nazi I. et al. Platetet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94: 850-856.
  56. George J.N. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009; 94: 759-762.
  57. Palm F., Urbanek C., Grau A. Infection, its treatment and the risk for stroke. Curr Vase Pharmacol 2009; 7: 146-152.
  58. Charlett A., Dobbs R.J., Dobbs S.M. et al. Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathog 2009; 1: 20.
  59. Kountouras J., Boziki M., Gavalas E. et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 2009; 256: 758-767.
  60. Franceschi F., Navarese E.P., Mollo R. et al. Helicobacter pylori and atherosclerosis. A review of the literature. Recenti Prog Med 2009; 100: 91-96.
  61. Longo-Mbenza B. Helicobacter pylori and atherosclerosis: can current data be useful for clinical practice? Int J Cardiol 2009; 135: e76-e77.
  62. Ayada K., Yokota K., Kobayashi K. et al. Chronic infections and atherosclerosis. Clin Rev Allergy Immunol 2009; 37: 44-48.
  63. Franceschi F., Niccoli G., Ferrante G. et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 2009; 202: 535-542.
  64. Chen Y., Blaser M.J. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 2007; 167: 821-827.
  65. Fullerton D., Britton J.R., Lewis S.A. et al. Helicobacter pylori and lung function, asthma, atopy and allergic disease - a population-based cross-sectional study in adults. Int J Epidemiol 2009; 38: 419-426.
  66. Ioannou G.N., Weiss N.S., Kearney D.J. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther 2005; 21: 765-772.
  67. Lahner E., Annibale B., Delle F.G. Systematic review: helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009; 29: 379-386.
  68. Bugdaci M.S., Zuhur S.S., Sokmen M. et al. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter 2011; 16: 124-130.
  69. Pierantozzi M., Pietroiusti A., Brusa L. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66: 1824-1829.
  70. Wroblewski L., Peek R., Wilson K. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 4: 713-739.
  71. Basso D., Zambon C.F., Letley D.P. et al. Clinical relevance of H. pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135: 91-99.
  72. Schmidt H., Ha D., Tayler E. et al. Variation in human genetic polymorphisms, their association with H. pylori acquisition and gastric cancer in a multi-ethnic country. J Gastroenterol Hepatol 2011; 26: 1725-1732.
  73. Gao L., Nieters A., Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet 2009; 12: 1658-1667.
  74. Snaith A., El-Omar E. Helicobacter pylori: host genetics and disease outcomes. Expert Rev Gastroenterol Hepatol 2008; 4: 577-585.
  75. Figueiredo C., Machado J.C., Pharoah P. et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94: 1680-1687.
  76. Gisbert J.P., Pajares J.M. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004; 20: 1001-1017.
  77. Gisbert J.P., de la M.F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921-1930.
  78. Deguchi R., Matsushima M., Suzuki T. et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterol 2009; 44: 713-716.
  79. Shimoyama T., Kato C., Kodama M. et al. Applicability of a monoclonal antibody-based stool antigen test to evaluate the results of Helicobacter pylori eradication therapy. Jpn J Infect Dis 2009; 62: 225-227.
  80. Calvet X., Lario S., Ramirez-Lazaro M.J. et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment. Helicobacter 2010; 15: 201-205.
  81. Schwarzer A., Lottspeich C., Russmann H. et al. Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children. Eur J Clin Microbiol Infect Dis 2007; 26: 475-480.
  82. Feldman R.A., Deeks J.J., Evans S.J. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995; 14: 428-433.
  83. Fauchere R.A., Charlier-Bret I.M., Courillon-Mallet A. et al. Evaluation comparative de 29 trousses commercialises pour !e diagnostic serologique de I'infection par Helicobacter pylori: etude multicentrique du Groupe d'etude Francais des Helicobacters (GEFH). Feuillet de Biologie 2011; 298: 25-32.
  84. Ekstrom A.M., Held M., Hansson L.E. et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 784-791.
  85. Lehours P., Ruskone-Fourmestraux A., Lavergne A. et al. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003; 98: 291-295.
  86. Kokkola A., Rautelin H., Puolakkainen P. et al. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. J Clin Microbiol 1998; 36: 1808-1810.
  87. Miki K., Ichinose M., Ishikawa K.B. et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84: 1086-1090.
  88. Levine A., Shevah O., Shabat-Sehayek V. et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004; 20: 117-122.
  89. Ozturk E., Yesilova Z., Ilgan S. et al. Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol 2009; 24: 1248-1251.
  90. Erzin Y., Altun S., Dobrucali A. et al. Evaluation of two enzyme immunoassays for detecting Helicobacter pylori in stool specimens of dyspeptic patients after eradication therapy. J Med Microbiol 2005; 54: 863-866.
  91. Asfeldt A.M., Lochen M.L., Straume B. et al. Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection. Scand J Gastroenterol 2004; 39: 1073-1077.
  92. Graham D.Y., Opekun A.R., Hammoud F. et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005-1009.
  93. Shirin H., Levine A., Shevah O. et al. Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion 2005; 71: 208-212.
  94. Gisbert J.P., Pajares J.M. 13C-urea breath test in the management of Helicobacter pylori infection. Dig Liver Dis 2005; 37: 899-906.
  95. Graham D.Y., Opekun A.R., Jogi M. et al. False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter 2004; 9: 17-27.
  96. Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357.
  97. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007; 56: 1502.
  98. Wenzhen Y., Yumin L., Quanlin G. et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103-1109.
  99. Oleastro M., Menard A., Santos A. et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41: 397-402.
  100. Cambau E., AHerheiligen V., Coulon C. et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47: 3600-3607.
  101. Glocker E., Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 2004; 42: 2241-2246.
  102. Woo H.Y., Park D.I., Park H. et al. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter 2009; 14: 22-28.
  103. Vecsei A., Innerhofer A., Binder C. et al. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin Gastroenterol Hepatol 2010; 8: 309-312.
  104. Kawai T., Yamagishi T., Yagi K. et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23 (Suppl 2): S171-S174.
  105. De Francesco V., Zullo A., Ierardi E. et al. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65: 327-332.
  106. Megraud F., Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
  107. Glupczynski Y., Broutet N., Cantagrel A. et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-552.
  108. Gatta L., Vakil N., Leandro G. et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-3079.
  109. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153.
  110. Gisbert J.P., Calvet X., O'Connor A. et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325.
  111. Vaira D., Zullo A., Vakil N. et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563.
  112. Essa A.S., Kramer J.R., Graham D.Y. et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-118.
  113. Gisbert J.P., Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011; 34: 604-617.
  114. Laine L., Hunt R., El-Zimaity H. et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazoleand tetracycline given with omeprazole versus omeprazole, amoxicillinand clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567.
  115. O'Morain C., Borody T., Farley A. et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415-420.
  116. Malfertheiner P., Bazzoli F., Delchier J.C. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazoleand tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913.
  117. Glupczynski Y., Megraud F., Lopez-Brea M. et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
  118. Megraud F., Coenen S., Versporten A. et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009. (in press).
  119. EMEA. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. European Medicines Evaluation Agency: London, 2004.
  120. Vallve M., Vergara M., Gisbert J.P. et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149-1156.
  121. Padol S., Yuan Y., Thabane M. et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-1475.
  122. Furuta T., Sugimoto M., Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxiciilin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 2007; 26: 693-703.
  123. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008: 31: 546-547.
  124. Calvet X., Garcia N., Lopez T. et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609.
  125. Ford A., Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 (Suppl B): 36B-40B.
  126. Fuccio L., Minardi M.E., Zagari R.M. et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562.
  127. Haydee B., Salvana A., Ang E.L.R. et al. Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology: 138,5, suppl. 1: S-340.
  128. Gisbert J.P., Gonzalez L., Calvet X. et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-1328.
  129. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 97-107.
  130. Sachdeva A., Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009; 29: 720-730.
  131. Tong J.L., Ran Z.H., Shen J. et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155-168.
  132. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on H. pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009; 1: 45-53.
  133. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079.
  134. Broutet N., Tchamgoue S., Pereira E. et al. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
  135. Abdullahi M., Annibale B., Capoccia D. et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450-1454.
  136. Suzuki T., Matsuo K., Ito H. et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-224.
  137. Rokkas T., Sechopoulos P., Robotis I. et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21-25.
  138. Lee J.M., Breslin N.P., Hyde D.K. et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496.
  139. Gisbert J.P., Gisbert J.L., Marcos S. et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-354.
  140. Lee B.H., Kirn N., Hwang T.J. et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45.
  141. Luther J., Higgins P.D., Schoenfeld P.S. et al. Empiric quadruple vs. tripte therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
  142. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44.
  143. Saad R.J., Schoenfeld P., Kirn H.M. et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-496.
  144. Lamouliatte H., Megraud F., Delchier J. et al. Second-line treatment for failure to eradicate H. pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18: 791-797.
  145. Cammarota G., Martino A., Pirozza G. et al. High efficacy of 1-week doxycyline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for H. pylori infection. Aliment Pharmacol Ther 2004; 19: 789-795.
  146. Van der P.D., Katelaris P.H. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007; 26: 1537-1542.
  147. Gisbert J., Calvet X. Review article: rifabutin in the treatment of refractory H. pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221.
  148. Ford A.C., Malfertheiner P., Giguere M. et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361-7370.
  149. Gisbert J.P., Gisbert J.L., Marcos S. et al. Helicobacter pylori first-line treatment and rescue options in
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.